Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Journey Medical (DERM) EBIT Margin (2020 - 2025)

Journey Medical (DERM) has disclosed EBIT Margin for 6 consecutive years, with 8.98% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT Margin rose 1080.0% year-over-year to 8.98%, compared with a TTM value of 9.35% through Sep 2025, up 3775.0%, and an annual FY2024 reading of 24.36%, down 2089.0% over the prior year.
  • EBIT Margin was 8.98% for Q3 2025 at Journey Medical, up from 19.16% in the prior quarter.
  • Across five years, EBIT Margin topped out at 49.93% in Q3 2023 and bottomed at 90.02% in Q2 2021.
  • Average EBIT Margin over 5 years is 28.6%, with a median of 25.3% recorded in 2025.
  • Peak annual rise in EBIT Margin hit 11215bps in 2023, while the deepest fall reached -7447bps in 2023.
  • Year by year, EBIT Margin stood at 51.7% in 2021, then dropped by -21bps to 62.78% in 2022, then surged by 179bps to 49.37% in 2023, then crashed by -67bps to 16.4% in 2024, then crashed by -155bps to 8.98% in 2025.
  • Business Quant data shows EBIT Margin for DERM at 8.98% in Q3 2025, 19.16% in Q2 2025, and 25.3% in Q1 2025.